(A) Monthly drug costs of patients in the ESAs group and Roxadustat group. حسب Jie Liu (15128)

الموضوعات:

PSM and Heckman regression results. حسب Qi Zhang (28502)

الموضوعات:

Study data. حسب Jie Liu (15128)

الموضوعات:

Regression results from a business risk perspective. حسب Qi Zhang (28502)

الموضوعات:

Mean hemoglobin levels of Roxadustat and ESAs groups over time. حسب Jie Liu (15128)

الموضوعات:

Fig 4 - حسب Maryann S. Watson (16879881)

الموضوعات:

Morisky score for ESAs group and Roxadustat group. حسب Jie Liu (15128)

الموضوعات:

Other robustness test regression results. حسب Qi Zhang (28502)

الموضوعات:

Species counts for all trap (kubben) catches across sites and seasons. حسب Maryann S. Watson (16879881)

الموضوعات:

Fig 5 - حسب Maryann S. Watson (16879881)

الموضوعات:

Association between current exposure to anti-rheumatic agents and ischemic stroke, with non-exposure and past exposure to each anti-rheumatic agent as reference. حسب Soo Min Ahn (10333246)

الموضوعات:

Species counts per catch for all fyke catches across sites and seasons. حسب Maryann S. Watson (16879881)

الموضوعات:

Baseline regression results. حسب Qi Zhang (28502)

الموضوعات:

Study population selection. حسب Soo Min Ahn (10333246)

الموضوعات:

Baseline characteristics of cases and controls. حسب Soo Min Ahn (10333246)

الموضوعات:

Risk of ischemic stroke according to the use of each anti-rheumatic agents. حسب Soo Min Ahn (10333246)

الموضوعات:

Univariate analysis results. حسب Qi Zhang (28502)

الموضوعات:

Patient flow diagram. حسب Jie Liu (15128)

الموضوعات:

Regression results for heterogeneity in corporate life cycle. حسب Qi Zhang (28502)

الموضوعات:

Mean total cholesterol levels over time in the roxadustat group (A) and ESAs group (B) according to the statins subgroup. حسب Jie Liu (15128)

الموضوعات: